China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
0.479
-0.051 (-9.64%)
At close: Nov 4, 2024, 4:00 PM
0.488
+0.009 (1.90%)
After-hours: Nov 4, 2024, 7:49 PM EST
China SXT Pharmaceuticals Employees
China SXT Pharmaceuticals had 75 employees as of March 31, 2024. The number of employees decreased by 3 or -3.85% compared to the previous year.
Employees
75
Change (1Y)
-3
Growth (1Y)
-3.85%
Revenue / Employee
$25,713
Profits / Employee
-$41,314
Market Cap
1.66M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Avinger | 72 |
cbdMD | 52 |
Tenon Medical | 21 |
Catheter Precision | 14 |
Cyclacel Pharmaceuticals | 12 |
Altamira Therapeutics | 10 |
Revelation Biosciences | 9 |
60 Degrees Pharmaceuticals | 3 |
SXTC News
- 4 weeks ago - China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency - GlobeNewsWire
- 1 year ago - China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule - GlobeNewsWire
- 1 year ago - China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million - GlobeNewsWire
- 3 years ago - Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC). - Accesswire
- 3 years ago - China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment - GlobeNewsWire
- 3 years ago - China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares - GlobeNewsWire